Demographic and clinical characteristics in CHANCE clopidogrel–aspirin patients with and without stroke within 90 days after index events
| Characteristics | Clopidogrel plus aspirin | p Value | ||
| Overall (2584) | No stroke (n=2372) | Stroke (n=212) | ||
| Age, median (IQR), year | 62.7 (54.9–71.5) | 62.4 (54.9–71.5) | 64.1 (55.9–71.9) | 0.20 |
| Female, n (%) | 852 (33.0) | 770 (32.5) | 82 (38.7) | 0.07 |
| Medical history, n (%) | ||||
| Previous TIA or stroke | 595 (23.0) | 547 (23.1) | 48 (22.6) | 0.89 |
| Hypertension | 1716 (66.4) | 1558 (65.7) | 158 (74.5) | 0.009 |
| Diabetes mellitus | 550 (21.3) | 494 (20.8) | 56 (26.4) | 0.06 |
| Dyslipidaemia | 290 (11.2) | 260 (11.0) | 30 (14.2) | 0.16 |
| Myocardial infarction | 43 (1.7) | 40 (1.7) | 3 (1.4) | 0.99 |
| Angina | 97 (3.8) | 93 (3.9) | 4 (1.9) | 0.14 |
| Known atrial fibrillation or flutter | 89 (3.4) | 84 (3.5) | 5 (2.4) | 0.37 |
| Current or previous smoking, n (%) | 1116 (43.2) | 1041 (43.9) | 75 (35.4) | 0.02 |
| High blood pressure at baseline | 1997 (77.3) | 1829 (77.1) | 168 (79.2) | 0.48 |
| Serum creatinine, mean (SD), umol/L | 73.9 (23.5) | 74.0 (23.5) | 72.7 (23.4) | 0.52 |
| Haemoglobin, mean (SD), g/L | 139.9 (18.1) | 139.9 (17.9) | 139.6 (20.2) | 0.93 |
| BMI at admission, median (IQR), kg/m2 | 24.5 (22.6–26.4) | 24.4 (22.6–26.3) | 25.1 (23.0–26.8) | 0.02 |
| Baseline NIHSS score, n (%) | <0.001 | |||
| 0 | 237 (9.2) | 227 (9.6) | 10 (4.7) | |
| 1 | 539 (20.9) | 507 (21.4) | 32 (15.1) | |
| 2 | 1278 (49.5) | 1180 (49.7) | 98 (46.2) | |
| 3 | 530 (20.5) | 458 (19.3) | 72 (34.0) | |
| Time from onset to randomisation, n (%) | 0.005 | |||
| <12 hours | 1293 (50.0) | 1168 (49.2) | 125 (59.0) | |
| ≥12 hours | 1291 (50.0) | 1204 (50.8) | 87 (41.0) | |
| Open-label aspirin dose at day 1, n (%) | <0.001 | |||
| ≤100 mg | 1478 (57.2) | 1373 (57.9) | 105 (49.5) | |
| 100–300 mg | 527 (20.4) | 490 (20.7) | 37 (17.5) | |
| ≥300 mg | 579 (22.4) | 509 (21.5) | 70 (33.0) | |
| History of hypertension and the BP control within 90 days | 0.02 | |||
| No hypertension and normal BP, n (%) | 421 (16.3) | 399 (16.8) | 22 (10.4) | |
| No hypertension and high BP, n (%) | 447 (17.3) | 415 (17.5) | 32 (15.1) | |
| Hypertension and normal BP, n (%) | 523 (20.2) | 483 (20.4) | 40 (18.9) | |
| Hypertension and high BP, n (%) | 1193 (46.2) | 1075 (45.3) | 118 (55.7) | |
| History of diabetes and antidiabetic therapy within 90 days | 0.16 | |||
| No diabetes, n (%) | 2034 (78.8) | 1878 (79.2) | 156 (73.6) | |
| Diabetes and no therapy, n (%) | 232 (9.0) | 208 (8.8) | 24 (11.3) | |
| Diabetes and therapy, n (%) | 316 (12.2) | 284 (12.0) | 32 (15.1) | |
| Lipid-lowering therapy, n (%) | 1096 (42.7) | 1023 (43.5) | 73 (34.4) | 0.01 |
| Qualifying event | 0.35 | |||
| TIA, n (%) | 717 (27.7) | 664 (28.0) | 53 (25.0) | |
| Minor ischaemic stroke, n (%) | 1867 (72.3) | 1708 (72.0) | 159 (75.0) | |
| ICAS*, n (%) | 231 (43.5) | 205 (41.9) | 26 (61.9) | 0.01 |
*Among 2548 patients, 531 were available for imaging data.
High blood pressure is defined as systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg.
BMI, body mass index; BP, blood pressure; CHANCE, Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events; NIHSS, National Institute of Health Stroke Scale; ICAS, intracranial arterial stenosis; TIA, transient ischaemic attack.